Century Therapeutics (IPSC) Common Equity (2020 - 2026)
Century Therapeutics (IPSC) posted quarterly Common Equity of $264.7 million for Q1 2026, up 10.11% year-over-year from $240.4 million in Q1 2025, and up 66.57% quarter-over-quarter from $158.9 million in Q4 2025.
Century Therapeutics (IPSC) Common Equity (2020 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has reported Common Equity for 7 consecutive years, with $264.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 10.11% year-over-year to $264.7 million; the TTM figure through Mar 2026 stood at $264.7 million (up 10.11% YoY), while the FY2025 annual figure was $158.9 million, down 1.5% from the prior year.
- Common Equity climbed to $264.7 million in Q1 2026 per IPSC's latest filing, from $158.9 million in the prior quarter.
- Across five years, Common Equity topped out at $386.7 million in Q1 2022 and bottomed at $158.9 million in Q4 2025.
- Historically, Common Equity has averaged $242.0 million across 5 years, with a median of $222.1 million in 2024.
- Annual changes were most pronounced in 2022 — Common Equity soared 522.32% — and 2023, when it sank 38.97%.
- Century Therapeutics' Common Equity stood at $302.7 million in 2022, then tumbled by 38.97% to $184.8 million in 2023, then declined by 12.66% to $161.4 million in 2024, then decreased by 1.5% to $158.9 million in 2025, then surged by 66.57% to $264.7 million in 2026.
- Business Quant data shows IPSC's Common Equity at $264.7 million in Q1 2026, $158.9 million in Q4 2025, and $176.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Century Therapeutics | 346.65 Mn | 86.58 Mn | - | 232.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 232.35 Mn |
| Mar 31, 2026 | 264.74 Mn |
| Dec 31, 2025 | 158.94 Mn |
| Sep 30, 2025 | 176.35 Mn |
| Jun 30, 2025 | 209.90 Mn |
| Mar 31, 2025 | 240.44 Mn |
| Dec 31, 2024 | 161.36 Mn |
| Sep 30, 2024 | 195.69 Mn |
| Jun 30, 2024 | 222.10 Mn |
| Mar 31, 2024 | 177.88 Mn |
| Dec 31, 2023 | 184.75 Mn |
| Sep 30, 2023 | 219.23 Mn |
| Jun 30, 2023 | 247.57 Mn |
| Mar 31, 2023 | 277.18 Mn |
| Dec 31, 2022 | 302.74 Mn |
| Sep 30, 2022 | 330.21 Mn |
| Jun 30, 2022 | 357.95 Mn |
| Mar 31, 2022 | 386.66 Mn |
| Dec 31, 2021 | 396.24 Mn |
| Sep 30, 2021 | 422.99 Mn |